J Pathol Transl Med.  2022 Jan;56(1):22-31. 10.4132/jptm.2021.08.31.

Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas

Affiliations
  • 1Department of Pathology, Keimyung University Dongsan Medical Center, Daegu, Korea

Abstract

Background
Pituitary tumor transforming gene 1 (PTTG1), paired-like homeodomain 2 (PITX2), and galectin-3 have been widely studied as predictive biomarkers for various tumors and are involved in tumorigenesis and tumor progression. We evaluated the usefulness of PTTG1, PITX2, and galectin-3 as predictive biomarkers for invasive non-functioning pituitary adenomas (NFPAs) by determining the relationship between the expressions of these three proteins and the invasiveness of the NFPAs. We also investigated whether PTTG1, E-cadherin, and Ki-67, which are known to be related to each other, show a correlation with NFPA features.
Methods
A retrospective study was conducted on 87 patients with NPFAs who underwent surgical removal. The NFPAs were classified into three groups based on magnetic resonance imaging findings of suprasellar extension and cavernous sinus invasion. Immunohistochemical staining for PTTG1, PITX2, galectin-3, E-cadherin, and Ki-67 was performed on tissue microarrays.
Results
PTTG1 expression showed a statistically significant correlation with the invasiveness of NFPAs, whereas PITX2 and galectin-3 did not have a relationship with the invasiveness of NFPAs. Moreover, there was no association among PTTG1, E-cadherin, and Ki-67 expression.
Conclusions
PTTG1 has the potential to serve as a predictive biomarker for invasive NFPA. Furthermore, this study may serve as a reference for the development of PTTG1-targeted therapeutic agents.

Keyword

Non-functioning pituitary adenomas; Pituitary tumor transforming gene expression; Invasiveness

Figure

  • Fig. 1 Invasiveness groups of non-functioning pituitary adenoma (NFPA) based on suprasellar extension (SSE) and cavernous sinus invasion (CSI) on magnetic resonance imaging (MRI). The representative MRI images of SSE (arrows) and CSI (arrowheads) are shown. NFPAs were classified into three groups based on the MRI findings: group I, neither SSE nor CSI; group II, only one of SSE or CSI; group III, both SSE and CSI.

  • Fig. 2 Scoring of immunohistochemical staining for pituitary tumor transforming gene (PTTG1), paired-like homeodomain 2 (PITX2), and galectin-3. The intensity of immunohistochemical stains was scored from 0 (negative) to 3 (strong). PTTG1: a score of 0 was regarded as negative, scores of 1 and 2 were regarded as low, and a score of 3 was regarded as high expression. PITX2 and galectin-3: a score of 0 was regarded as negative, a score of 1 was regarded as low, and scores of 2 and 3 were regarded as high expression.

  • Fig. 3 Stacked column chart showing the ratio of pituitary tumor transforming gene (PTTG1) expression in each invasiveness group. As the level of invasiveness increased, the proportion of high PTTG1 expression tended to increase.

  • Fig. 4 Scoring of immunohistochemical staining for E-cadherin and Ki-67. E-cadherin: a score of 0 was regarded as negative, and scores of 1 to 3 were regarded as positive expression. Ki-67 index was measured by image analyzer, and two samples of the stain are shown.

  • Fig. 5 Box plots of the distribution of the tumor size by invasion group and recurrence. A larger tumor size was associated with higher invasiveness (A) and a higher recurrence rate (B).


Reference

References

1. Gadelha MR, Trivellin G, Hernandez Ramirez LC, Korbonits M. Genetics of pituitary adenomas. Front Horm Res. 2013; 41:111–40.
Article
2. Greenman Y, Cooper O, Yaish I, et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016; 175:63–72.
Article
3. Greenman Y, Tordjman K, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf). 2005; 63:39–44.
Article
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. Lyons: IARC Press;2004.
5. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO cassification of tumours of endocrine organs. Lyons: IARC Press;2012. p. 11–3.
6. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007; 156:203–16.
Article
7. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011; 114:336–44.
Article
8. Scoazec JY, Couvelard A, Reseau T. Classification of pancreatic neuroendocrine tumours: changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future. Ann Pathol. 2017; 37:444–56.
9. Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013; 126:123–35.
10. Matsuyama J. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo). 2012; 52:563–9.
Article
11. Chiloiro S, Doglietto F, Trapasso B, et al. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology. 2015; 101:143–50.
Article
12. Kim JS, Lee YS, Jung MJ, Hong YK. The predictive value of pathologic features in pituitary adenoma and correlation with pituitary adenoma recurrence. J Pathol Transl Med. 2016; 50:419–25.
Article
13. Mooney MA, Hardesty DA, Sheehy JP, et al. Rater reliability of the hardy classification for pituitary adenomas in the magnetic resonance imaging era. J Neurol Surg B Skull Base. 2017; 78:413–8.
Article
14. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996; 38:765–70.
Article
15. Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res. 2002; 35:561–5.
Article
16. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M. Biomarkers of pituitary neoplasms: a review (Part II). Neurosurgery. 2010; 67:1790–8.
Article
17. Sav A, Rotondo F, Syro LV, Scheithauer BW, Kovacs K. Biomarkers of pituitary neoplasms. Anticancer Res. 2012; 32:4639–54.
18. McCabe CJ, Khaira JS, Boelaert K, et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf). 2003; 58:141–50.
Article
19. Shah PP, Kakar SS. Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Lett. 2011; 311:66–76.
Article
20. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999; 285:418–22.
Article
21. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer. 2008; 15:721–43.
Article
22. Feng W, Xiaoyan X, Shenglei L, Hongtao L, Guozhong J. PTTG1 cooperated with GLI1 leads to epithelial-mesenchymal transition in esophageal squamous cell cancer. Oncotarget. 2017; 8:92388–400.
Article
23. Yoon CH, Kim MJ, Lee H, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem. 2012; 287:19516–27.
Article
24. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000; 156:899–909.
Article
25. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2002; 277:6852–7.
Article
26. Cottier JP, Destrieux C, Brunereau L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000; 215:463–9.
Article
27. Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999; 84:761–7.
Article
28. Raverot G, Wierinckx A, Dantony E, et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010; 95:1708–16.
Article
29. Li Y, Zhou LP, Ma P, et al. Relationship of PTTG expression with tumor invasiveness and microvessel density of pituitary adenomas: a meta-analysis. Genet Test Mol Biomarkers. 2014; 18:279–85.
Article
30. Trott G, Ongaratti BR, de Oliveira Silva CB, et al. PTTG overexpression in non-functioning pituitary adenomas: Correlation with invasiveness, female gender and younger age. Ann Diagn Pathol. 2019; 41:83–9.
Article
31. Filippella M, Galland F, Kujas M, et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf). 2006; 65:536–43.
Article
32. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ. Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 2009; 94:4406–13.
Article
33. Tamura R, Ohara K, Morimoto Y, et al. PITX2 expression in nonfunctional pituitary neuroendocrine tumor with cavernous sinus invasion. Endocr Pathol. 2019; 30:81–9.
Article
34. Acunzo J, Roche C, Defilles C, et al. Inactivation of PITX2 transcription factor induced apoptosis of gonadotroph tumoral cells. Endocrinology. 2011; 152:3884–92.
Article
35. Jin L, Riss D, Ruebel K, et al. Galectin-3 expression in functioning and silent ACTH-producing adenomas. Endocr Pathol. 2005; 16:107–14.
Article
36. Zhang Y, He N, Zhou J, Chen Y. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. Clin Imaging. 2011; 35:165–73.
Article
37. Righi A, Morandi L, Leonardi E, et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 2013; 44:2400–9.
Article
38. Qian ZR, Sano T, Yoshimoto K, et al. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (Ecadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol. 2007; 20:1269–77.
Article
39. Wong TS, Gao W, Chan JY. Interactions between E-cadherin and microRNA deregulation in head and neck cancers: the potential interplay. Biomed Res Int. 2014; 2014:126038.
Article
40. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999; 5:1317–21.
Article
41. Wang Z, Moro E, Kovacs K, Yu R, Melmed S. Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A. 2003; 100:3428–32.
Article
42. Mu YM, Oba K, Yanase T, et al. Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocr J. 2003; 50:771–81.
43. Yu R, Cruz-Soto M, Li Calzi S, Hui H, Melmed S. Murine pituitary tumor-transforming gene functions as a securin protein in insulin-secreting cells. J Endocrinol. 2006; 191:45–53.
Article
44. Dekkers OM, Karavitaki N, Pereira AM. The epidemiology of aggressive pituitary tumors (and its challenges). Rev Endocr Metab Disord. 2020; 21:209–12.
Article
45. Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012; 15:71–83.
Article
Full Text Links
  • JPTM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr